04:46 PM EDT, 09/13/2024 (MT Newswires) -- Eli Lilly ( LLY ) said late Friday that the US Food and Drug Administration has approved Ebglyss, or lebrikizumab-lbkz, for the treatment of moderate-to-severe atopic dermatitis that is not well-controlled with topical prescription medicines in individuals aged 12 years and older who weigh at least 88 pounds.

The approval is based on results from ADvocate 1, ADvocate 2 and ADhere trials. In ADvocate and 2 trials, 10% of people treated with Ebglyss showed clear or almost-clear skin as early as four weeks, while 5% who took the medication felt relief as early as two weeks, the company said.

Lilly said the drug will be available in the US in the coming weeks.

Price: 922.85, Change: -0.86, Percent Change: -0.09